Efficacy and Safety of Sodium Oligomannate in the Prevention of PSCI

Patients with acute ischemic stroke were recruited, and after signing informed consent, those who met the inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive treatment in the trial group (receiving sodium oligomannate)

the control group (receiving placebo capsule) for 24 weeks.